Chyawanprash Decoded

Claim Substantiation

In this section

01Scientific Basis for Claim Substantiation
02Evidence Hierarchy
03Clinical Evidence Supporting DCP
04Cellular and Functional Evidence
05Evidence Map Across Health Domains
06Potential Scientific Claim Territories
07Limitations and Future Directions
08Concluding Perspective

Scientific basis for claim substantiation

One formulation, eight interacting pathways

Considered together, the cellular and preclinical investigations reported in this review demonstrate activity across multiple interconnected biological domains.

These findings support the concept that DCP is a multi-component formulation capable of interacting with multiple biological pathways rather than acting through a single molecular target.

Reading this diagramEach band is a level of biological organisation. The order reflects the sequence in which evidence was generated, not a causal chain.

01Cellular energyATP availability
02Antioxidant defenceFree-radical scavenging
03Cellular protectionMuscle · lung · liver · neuronal
04Innate immune functionNK cells · macrophages · dendritic cells
05Inflammatory regulationIL-6 · IL-8 · CXCR3 signalling
06Allergy-associated responsesIgE · histamine
07Tissue-specific functionOsteoblasts · neurons · endothelium
08Cellular ageing pathwaysTelomerase · β-galactosidase

Scientific basis for claim substantiation

Dabur Chyawanprash (DCP) is a classical polyherbal formulation positioned within the Ayurvedic concept of Rasayana, traditionally associated with the maintenance of vitality, strength, resilience, immunity, nourishment, and healthy ageing. Unlike a single-ingredient botanical preparation, Chyawanprash represents a complex formulation comprising approximately 45+ Ayurvedic ingredients, including botanicals and traditional formulation components, with Amla (Phyllanthus emblica L.) as a principal ingredient.

The traditional concept of Rasayana encompasses multiple dimensions of health rather than a single therapeutic endpoint. These include maintenance of physical vitality, resistance to environmental and physiological stress, immune competence, respiratory wellbeing, nourishment of tissues, and preservation of functional capacity with advancing age.

Modern scientific investigation of such a complex formulation therefore requires a multidimensional evidence-generation strategy. A single biological assay, biomarker, or molecular target cannot adequately represent the potential biological activity of the complete formulation.

Accordingly, the scientific programme for DCP has incorporated complementary levels of evidence encompassing:

The objective of the claim-substantiation programme was to determine whether the broad health concepts traditionally associated with Chyawanprash could be translated into measurable biological, physiological, and clinical endpoints. The investigations have explored interconnected domains including:

Traditional Ayurvedic knowledge and formulation rationale
Quality and compositional characterization
In-vitro functional screening
Cellular and molecular investigations
Preclinical efficacy models
Clinical investigations
Clinical laboratory and biomarker assessments
Mechanistic pathway investigations
Emerging systems-biology approaches

Energy and stamina
Muscle health and cellular protection
Antioxidant defence
Immune responsiveness
Innate immune activation
Allergy-associated responses
Respiratory wellbeing
Cardiovascular cellular health
Liver-cell protection
Bone-cell activity
Neuronal protection
Cellular vitality
Oxidative-stress resilience
Inflammatory regulation
Cellular ageing-associated pathways
Genoprotective activity

The resulting evidence therefore represents a continuum from traditional positioning to measurable biological effects and human observations.

Biological rationaleThis approach is particularly relevant to DCP because biological activity may arise from the combined and potentially complementary actions of multiple phytoconstituents acting across several biological pathways.

Evidence Hierarchy

From traditional positioning to scientific claim substantiation

Ayurvedic Rasayana concept
Formulation composition and quality
Cellular and functional activity
Mechanistic pathway modulation
Preclinical biological effects
Human clinical and laboratory findings
Scientific claim substantiation

The scientific evidence generated for DCP can be considered across different levels of biological relevance.

The combination of these evidence levels provides a more comprehensive scientific interpretation than any individual study considered in isolation.

Weight of evidenceImportantly, the evidentiary weight of a finding depends on the level at which it was generated. Clinical findings provide human evidence, whereas cellular and molecular studies primarily provide biological plausibility and mechanistic support.

Evidence hierarchy for DCP claim substantiation

Traditional and formulation rationale

The traditional use of Chyawanprash as a Rasayana provides the conceptual foundation for investigating domains such as vitality, resilience, immunity, respiratory wellbeing, tissue nourishment, and healthy ageing.

Formulation and quality evidence

The approximately 45-ingredient formulation architecture, raw-material quality controls, manufacturing processes, and compositional characterization establish the identity and consistency of the formulation being investigated.

Clinical evidence

Human studies provide direct evidence regarding biological, physiological, and functional outcomes in human populations and therefore represent an important component of claim substantiation.

Human laboratory and biomarker evidence

Clinical investigations have incorporated measurable laboratory and physiological parameters, including immunological, inflammatory, respiratory, biochemical, and cytogenetic endpoints.

Preclinical evidence

Relevant preclinical models provide controlled experimental systems for evaluating biological effects and exploring potential mechanisms.

Cellular and molecular evidence

In-vitro investigations provide mechanistic insights into cellular energy metabolism, immune-cell function, oxidative stress, inflammatory signaling, cellular protection, neuronal function, and ageing-associated pathways.

Clinical Evidence Supporting DCP

Clinical evidence supporting DCP

Clinical investigations represent an important component of the scientific evidence supporting the biological and functional positioning of DCP.

The clinical programme has evaluated DCP in different populations and health contexts, including:

Adults with seasonal respiratory/allergic complaints
Individuals experiencing seasonal influenza
Healthy school-going children
Healthy individuals evaluated in the context of COVID-19
Individuals exposed to tobacco smoke and evaluated for cytogenetic damage

The studies have incorporated both clinical outcomes and laboratory or biomarker endpoints, allowing DCP to be evaluated from functional, physiological, and biological perspectives.

DCP – Nasal Allergies and Viral Infections

A clinical investigation evaluated DCP in adults with normal health status and in individuals presenting with allergy, viral, or bacterial respiratory infections.

The study assessed:

IgE
IgG
Complement C3
Complement C4
Haemoglobin
ESR
Respiratory parameters
Quality-of-life measures

Reduction in IgE was reported in a substantial proportion of participants, together with improvements in selected clinical and laboratory parameters.

Scientific interpretationThe findings provide human evidence that DCP may influence selected allergy-associated and respiratory health parameters. The accompanying laboratory observations provide biological support for investigating the traditional positioning of Chyawanprash in relation to respiratory resilience. These observations are complemented by experimental anti-allergy and respiratory cellular studies.

Open the study page

DCP – Seasonal Influences

A double-blind, placebo-controlled clinical study evaluated DCP in adults aged 15–75 years with non-specific seasonal complaints.

The study assessed:

Symptoms
Haemoglobin
Total leukocyte count
Differential leukocyte count
ESR
Pulmonary function test parameters
Cortisol
IgE
C3/C4
Biochemical parameters

The study reported improvements in symptoms and selected pulmonary, laboratory, and biochemical parameters.

Scientific interpretationThe findings provide human evidence relevant to seasonal respiratory wellbeing and physiological resilience. Importantly, these observations should be interpreted as evidence of beneficial changes in the parameters evaluated in the study. They cannot, on their own, be interpreted as evidence of prevention or treatment of influenza unless such an outcome was specifically demonstrated by the study design.

Open the study page

DCP – Healthy School-Going Children

A prospective, randomized, open-label study evaluated Chyawanprash in healthy school-going children aged 5–12 years.

The study assessed:

Frequency of infection/allergy episodes
Severity and duration of illness
Energy
Fitness
Growth
Stamina
Screening parameters
Quality of life
Safety

The study reported a lower number and duration of illness episodes, lower absenteeism, and improvement in selected wellbeing and quality-of-life parameters.

Scientific interpretationThese findings support the traditional positioning of Chyawanprash in relation to general health, vitality, resilience, and wellbeing in children. The findings also provide a clinical context for the immune-modulatory and cellular-protection observations generated in experimental studies.

Open the study page

DCP – COVID-19 Community Study

A multicentre, randomized, comparative, prospective community study was conducted in healthy individuals aged 5–70 years.

The study assessed:

COVID-19 incidence
RT-PCR/antigen testing
WHO ordinal scale
ILI/ALRI-related parameters
Symptoms
Quality of life
Safety

The DCP group demonstrated lower observed COVID-19 positivity and favourable quality-of-life observations, while reported adverse events were mild and were not considered clearly related to the intervention.

Scientific interpretationThe study provides human evidence generated during the COVID-19 pandemic regarding the potential association of DCP use with respiratory and immune-related health outcomes. However, COVID-19 prevention represents a specific clinical claim. Therefore, the findings should be presented according to the actual study design, population, endpoints, and statistical evidence and should not be generalized to broad claims of protection against infectious diseases without appropriate clinical substantiation.

Open the study page

Genoprotective Efficacy of Chyawanprash in Bidi Smokers

A separate clinical investigation evaluated the potential genoprotective efficacy of Dabur Chyawanprash Awaleha in individuals exposed to tobacco smoke through bidi smoking.

The study included:

25 male bidi smokers in the Chyawanprash intervention group
25 individuals matched for age, sex, and social status as the control group
Chyawanprash administration at 20 g/ twice daily for two months, administered twice daily

The investigation evaluated several cytogenetic parameters:

Mitotic Index (MI)
Chromosomal Aberrations (CA)
Sister Chromatid Exchanges (SCE)
Satellite Associations (SA)

These endpoints provide information regarding chromosomal integrity and cellular responses associated with exposure to genotoxic environmental agents.

Key findings

Compared with bidi smokers, the Chyawanprash-fed group demonstrated a significant reduction in measured cytogenetic abnormalities (P < 0.01).
The frequency of chromosomal aberrations was reported to decrease to approximately 1.00 in Chyawanprash-fed smokers, approaching the frequency observed in the non-smoking control group (0.88).
The reduction was observed across the evaluated cytogenetic parameters.

Scientific interpretationThe study provides human evidence supporting a potential genoprotective effect of Chyawanprash in the context of tobacco-smoke-associated cytogenetic damage. The findings are particularly relevant when considered alongside the antioxidant and cellular-protection properties demonstrated in other DCP investigations. Tobacco smoke contains numerous reactive and potentially mutagenic constituents, and the reduction in cytogenetic abnormalities observed following Chyawanprash consumption provides evidence warranting further investigation of its potential role in cellular and genomic stress protection. The findings, however, remain within the scope of the study and do not establish that Chyawanprash prevents tobacco-induced cancer or eliminates the health risks associated with smoking.

Scientifically appropriate claimChyawanprash demonstrated genoprotective activity, evidenced by reduction in tobacco-smoke-associated cytogenetic abnormalities in a human study.

For broader consumer-oriented communication, a more conservative interpretation would be: Supports cellular protection against oxidative and environmental stress.

Open the study page

Collectively, these studies provide a human evidence base spanning respiratory wellbeing, allergy-associated responses, immune-related resilience, general wellbeing, and cellular/genomic protection.

Summary of Clinical Evidence

Clinical domain	Population	Major endpoints	Principal observation
Respiratory/allergy health	Adults	IgE, complement, inflammatory and respiratory parameters	Reduction in IgE and improvement in selected parameters
Seasonal respiratory illness	Adults	Symptoms, PFT, IgE, inflammatory and biochemical parameters	Improvement in symptoms and selected parameters
General wellbeing	Healthy children	Illness frequency/duration, energy, fitness, QoL	Lower illness burden and improvement in selected wellbeing parameters
Respiratory/immune resilience	Healthy individuals	COVID-19 incidence, testing, symptoms, QoL	Lower observed positivity and favourable QoL observations
Genoprotection	Bidi smokers	MI, CA, SCE, SA	Significant reduction in cytogenetic abnormalities

Cellular and Functional Evidence

Cellular and functional evidence supporting claim substantiation

The clinical evidence is complemented by a broad programme of in-house cellular and functional investigations. These studies were designed not only to demonstrate biological activity but also to establish biological plausibility and provide mechanistic context for the health domains investigated clinically.

Energy and cellular vitality2.2-fold

DCP increased intracellular ATP levels by approximately 2.2-fold in human peripheral blood mononuclear cells (PBMCs) compared with untreated cells. ATP represents the primary cellular energy currency required for numerous biological processes.

Scientific interpretationThe observed increase indicates that DCP can influence cellular energy availability under the experimental conditions and provides mechanistic support for investigating DCP in relation to: cellular vitality, energy metabolism and physiological resilience. The finding represents cellular evidence of enhanced ATP availability and should not be interpreted as direct evidence of increased physical stamina in humans.

Muscle-cell protection77%

In an experimentally induced muscle-cell damage model, DCP demonstrated approximately 77% restoration of cellular viability.

Scientific interpretationThe finding indicates a protective effect under the experimental conditions and provides biological support for investigating DCP in relation to muscle-cell resilience and cellular stress protection.

Antioxidant protection86%

DCP demonstrated approximately 86% free-radical scavenging activity in the experimental assay. Oxidative stress results from an imbalance between reactive species and antioxidant defence mechanisms. Excessive oxidative stress can affect cellular lipids, proteins, membranes, and nucleic acids.

Scientific interpretationThe observed free-radical scavenging activity provides experimental evidence of the antioxidant potential of DCP. This finding is particularly relevant to the broader scientific hypothesis that antioxidant activity may contribute to cellular protection and resilience-associated effects.

Respiratory cellular protection61% · 56%

In a lung-cell oxidative damage model, DCP demonstrated approximately 61% restoration of cellular viability and approximately 56% inhibition of IL-8. IL-8 is an inflammatory chemokine involved in immune-cell recruitment and inflammatory activation.

Scientific interpretationThe combined cellular-protection and inflammatory-modulation findings provide mechanistic support for the respiratory health observations obtained in clinical investigations.

Cardiovascular cellular health54%

DCP demonstrated approximately 54% inhibition of IL-6 in human endothelial cells. IL-6 is a multifunctional cytokine involved in inflammatory signaling.

Scientific interpretationThe finding indicates modulation of inflammatory signaling in endothelial cells and provides preliminary cellular evidence relevant to vascular inflammatory balance. It should be positioned as cardiovascular cellular evidence, rather than evidence for prevention or treatment of cardiovascular disease.

Liver-cell protection74%

DCP demonstrated approximately 74% restoration of liver-cell viability following experimentally induced cellular damage.

Scientific interpretationThe observation demonstrates hepatocellular protection under the experimental conditions and provides a basis for further investigation of DCP in relation to liver cellular resilience.

Bone-cell activity118%

DCP increased osteoblast proliferation by approximately 118% compared with untreated cells. Osteoblasts are bone-forming cells and play a central role in bone tissue formation and maintenance.

Scientific interpretationThe finding demonstrates stimulation of osteoblast proliferation under experimental conditions and provides preliminary cellular evidence relevant to bone-cell activity.

Neuronal protection and connectivity53% · 2.5-fold

DCP demonstrated approximately 53% protection of neuronal-cell viability against induced damage and an approximately 2.5-fold increase in neurite formation. Neurite formation is an important cellular process associated with neuronal development and connectivity.

Scientific interpretationThe findings provide evidence for neuronal cellular protection and enhanced neurite formation under experimental conditions and establish a foundation for future research into neuronal resilience and healthy cognitive ageing.

Immunomodulatory Activity

NK-cell activity. DCP increased NK-cell activity from approximately 24.6% in control cells to 79.6% at 20 μg/mL, corresponding to an approximately 3.2-fold increase. Natural killer cells form an important component of innate immune surveillance. The finding demonstrates that DCP can enhance NK-cell functional activity under the experimental conditions and provides mechanistic support for its immune-resilience positioning.

Dendritic-cell activation. DCP increased secretion of several immune mediators from dendritic cells: TNF-α up to 5.2-fold, IL-1β up to 2.2-fold and MIP-1α up to 3.3-fold. Dendritic cells are important antigen-presenting cells linking innate and adaptive immune responses. The observed changes demonstrate that DCP can modulate dendritic-cell signaling and support investigation of its effects on immune-cell communication. Because immune activation can have context-dependent effects, these findings are appropriately described as immunomodulatory activity rather than simply “immune boosting.”

Macrophage functional activity. DCP enhanced zymosan-particle phagocytosis by approximately 28.9–65.2% in RAW 264.7 macrophages. Phagocytosis is a fundamental macrophage function contributing to innate immune defence and cellular clearance. The finding demonstrates enhanced macrophage functional activity under experimental conditions and provides complementary evidence to the NK-cell and dendritic-cell findings.

Together, these observations indicate that DCP influences multiple components of innate immune-cell function.

Control cells24.6%

DCP 20 μg/mL79.6%

NK-cell activity, approximately 3.2-fold increase.

TNF-α5.2-fold

MIP-1α3.3-fold

IL-1β2.2-fold

Dendritic-cell mediators, maximum fold increase.

Anti-Allergy Activity

DCP significantly reduced ovalbumin-induced serum IgE responses, with approximately 12-fold reduction at Day 14 and 41-fold reduction at Day 21.

DCP also significantly suppressed allergen-induced plasma histamine release and maintained histamine concentrations closer to baseline following allergen challenge.

The findings complement the clinical evidence generated in individuals with allergy and respiratory complaints.

Scientific interpretationThese findings provide experimental evidence for modulation of pathways associated with allergic responses: Allergen exposure → IgE response → mediator release → allergic response.

Cellular Ageing and Resilience

The DCP research programme has investigated biological pathways associated with cellular ageing. The observations included:

3.4-fold increase in telomerase activity
71% inhibition of β-galactosidase activity
52% inhibition of CXCR3-associated inflammatory signalling

These findings were complemented by observations related to oxidative stress and inflammatory regulation.

Scientific interpretationThe combined findings suggest that DCP influences several biological processes relevant to cellular resilience and ageing-associated pathways. However, these observations should be regarded as mechanistic and hypothesis-generating evidence. They should not be interpreted as direct evidence that DCP slows biological ageing or extends lifespan in humans.

Integrated biological evidence

Integrated biological activity

When considered together, the cellular and preclinical investigations demonstrate that DCP exhibits activity across multiple interconnected biological domains.

These findings collectively support the concept that DCP is a multi-component formulation capable of interacting with multiple biological pathways rather than acting through a single molecular target. The framework should be regarded as an integrated biological interpretation rather than a proven linear causal pathway.

01Cellular energy↑ ATP
02Antioxidant defenceFree-radical scavenging
03Cellular protectionMuscle, lung, liver, neuronal cells
04Innate immune functionNK cells, macrophages, dendritic cells
05Inflammatory regulationIL-6, IL-8, CXCR3-associated signalling
06Allergy-associated responsesIgE, histamine
07Tissue-specific cellular functionOsteoblasts, neuronal cells, endothelial cells
08Cellular ageing-associated pathwaysTelomerase, β-galactosidase

Consolidated evidence supporting key health domains

Health domain	Key experimental observation	Scientific interpretation
Energy and cellular vitality	ATP increased approximately 2.2-fold in PBMCs	Supports cellular energy availability
Muscle cellular protection	Approximately 77% restoration of viability	Supports cellular resilience
Antioxidant protection	Approximately 86% free-radical scavenging	Supports antioxidant potential
Immunomodulation	NK activity increased approximately 3.2-fold	Supports innate immune responsiveness
Dendritic-cell activity	TNF-α, IL-1β and MIP-1α increased	Supports modulation of immune signaling
Macrophage function	Phagocytosis increased 28.9–65.2%	Supports innate immune-cell function
Allergy-associated responses	IgE reduction of approximately 12-fold and 41-fold	Supports modulation of allergy-associated pathways
Histamine regulation	Suppression of allergen-induced histamine release	Supports modulation of immediate allergic responses
Respiratory cellular protection	61% viability restoration; 56% IL-8 inhibition	Supports respiratory cellular protection
Cardiovascular cellular health	54% IL-6 inhibition in endothelial cells	Supports vascular inflammatory modulation
Liver cellular protection	74% viability restoration	Supports hepatocellular protection
Bone-cell activity	118% increase in osteoblast proliferation	Supports bone-cell activity
Neuronal protection	53% protection; 2.5-fold increase in neurite formation	Supports neuronal cellular resilience
Cellular ageing-associated pathways	Telomerase ↑ 3.4-fold; β-galactosidase ↓ 71%; CXCR3 signaling ↓ 52%	Supports investigation of cellular resilience and ageing-associated pathways

Clinical-to-mechanistic evidence integration

An important strength of the DCP scientific programme is the ability to investigate selected health domains at more than one level of biological organization.

Domain	Clinical evidence	Cellular evidence	Integrated interpretation
Immune resilience	Human studies → immune and respiratory health observations.	NK-cell activation + macrophage phagocytosis + dendritic-cell signalling.	The clinical and cellular findings provide complementary evidence supporting further investigation of DCP in immune responsiveness and physiological resilience.
Respiratory health	Respiratory symptoms and physiological parameters.	Lung-cell protection + IL-8 modulation.	The findings provide complementary clinical and mechanistic evidence relevant to respiratory cellular protection and wellbeing.
Allergy-associated responses	IgE and allergy-associated parameters.	Preclinical evidence. IgE modulation + histamine suppression.	The evidence supports a biological rationale for investigating DCP in allergy-associated immune responses.
Cellular and genomic protection	Reduced chromosomal aberrations, SCE and other cytogenetic abnormalities in bidi smokers.	Antioxidant activity + protection against cellular damage.	The findings provide complementary evidence supporting a cellular-protection and genoprotective research hypothesis.

Evidence Map Across Health Domains

DCP evidence map across health domains

Health domain	Clinical evidence	Preclinical / cellular evidence
Immune resilience
Respiratory wellbeing
Allergy-associated responses
General wellbeing/vitality
Antioxidant protection	–
Cellular protection	–
Genoprotective activity		–
Energy metabolism	–
Muscle cellular protection	–
Liver cellular protection	–
Bone-cell activity	–
Neuronal protection	–
Cardiovascular cellular health	–
Cellular ageing/resilience	–

This evidence map illustrates that certain domains have both human and experimental support, whereas others currently remain supported primarily by cellular or preclinical observations.

Potential Scientific Claim Territories

Potential scientific claim territories

Based on the evidence generated to date, DCP can be scientifically investigated and positioned around several broad health domains.

Immune resilience

Supported by clinical immune/respiratory investigations, NK-cell activity, dendritic-cell responses and macrophage phagocytosis.

Respiratory wellbeing

Supported by clinical respiratory parameters, lung-cell protection, IL-8 modulation and allergy-associated endpoints.

Antioxidant and cellular protection

Supported by free-radical scavenging, cellular viability protection, liver, muscle, lung and neuronal cellular models, and genoprotective clinical observations.

General vitality and cellular energy

Supported by clinical wellbeing observations, ATP enhancement and cellular functional responses.

Allergy-associated immune responses

Supported by clinical IgE observations, experimental IgE modulation and histamine suppression.

Cellular resilience and healthy ageing

Supported primarily by telomerase activity, β-galactosidase activity, CXCR3-associated signaling, oxidative-stress modulation and cellular protection.

ScopeThese territories represent scientific areas supported by the available evidence, rather than automatically constituting consumer claims. Final claim language should be determined according to the intended market, regulatory framework, study design, statistical substantiation, and level of evidence.

Scientific interpretation of the overall evidence

The available evidence indicates that DCP has been investigated through a broad and progressively expanding scientific framework.

Clinical studies provide human evidence across areas including respiratory and allergy-associated health, seasonal illness, general wellbeing, and cytogenetic/genoprotective responses.

Preclinical studies extend these observations by investigating immune function, allergy-associated responses, tissue protection, and other physiological pathways under controlled experimental conditions.

Cellular studies provide mechanistic insights into energy metabolism, oxidative stress, immune-cell function, inflammatory signalling, cellular viability, neuronal function, osteoblast activity, and ageing-associated pathways.

The convergence of findings across these levels provides a scientifically coherent framework for understanding the potential biological activity of DCP.

However, the evidence should always be interpreted according to the level at which it was generated:

Clinical observations → human evidence
Human biomarkers → biological evidence in humans
Preclinical studies → biological support
Cellular/molecular studies → mechanistic insight

This hierarchy prevents overextension of experimental findings into clinical claims that have not yet been directly evaluated.

Quantitative biological evidence

Scope of this summaryThe following quantitative findings are drawn from in-house in-vitro functional assays and preclinical models. They represent mechanistic evidence supporting potential functional benefits rather than direct clinical outcomes.

I · Cellular energy, antioxidant and tissue protection

01Energy and staminaATP production

↑ 2.2-foldincrease in ATP levels in human PBMCs

02Muscle health and protectionCell viability

77%restoration of cell viability in muscle-cell damage model

03Antioxidant protectionFree-radical scavenging

86%free-radical scavenging activity

04Respiratory healthLung cell protection

61%restoration of lung-cell viability following oxidative damage

56%inhibition of IL-8 in lung cells

05Cardiovascular healthEndothelial cells

54%inhibition of IL-6 in human endothelial cells

06Liver healthHepatoprotection

74%restoration of liver-cell viability following cellular damage

07Bone healthOsteoblast activity

118%increase in osteoblast proliferation compared with untreated cells

08Neuronal healthNeuroprotection and connectivity

53%restoration of neuronal-cell viability against induced damage

~2.5-foldincrease in neurite formation

II · Cellular vitality and inflammaging pathways

09Cellular vitality and inflammagingAgeing-associated markers

↑ 3.4-foldincrease in telomerase activity

71%inhibition of β-galactosidase activity

52%inhibition of CXCR3-associated inflammatory signalling

III · Immunomodulation and innate immune activation

10Natural killer (NK) cell activityInnate immune response

24.6% → 79.6%NK-cell activity increased from 24.6% in control cells to 79.6% at 20 µg/mL, a ~3.2-fold increase

11Dendritic cell activationCytokine secretion

↑ 5.2-foldTNF-α at 500 µg/mL

↑ 2.2-foldIL-1β at 500 µg/mL

↑ 3.3-foldMIP-1α at 500 µg/mL

12Macrophage functionPhagocytic activity

28.9% – 65.2%increase in zymosan-particle internalization in RAW 264.7 macrophages

IV · Anti-allergy activity

13IgE modulationAllergen-induced IgE

~12-foldreduction in serum IgE at Day 14, ovalbumin-induced allergic model

~41-foldreduction in serum IgE at Day 21, ovalbumin-induced allergic model

14Histamine regulationAcute allergic response

~3-foldallergen challenge increased plasma histamine approximately 3-fold above baseline within 3 minutes; pre-treatment with DCP maintained histamine levels close to baseline and significantly suppressed histamine release across all evaluated time points

Read across sections III and IVInnate immune effector function is activated while allergen-driven IgE and histamine responses are suppressed: activation and restraint in the same formulation.

V · Summary of activity pillars

01Energy enhancementATP production in human PBMCs
02Antioxidant protectionFree-radical scavenging and cellular defence
03Immune activationNK cell, dendritic cell and macrophage function
04Allergy modulationSerum IgE and plasma histamine regulation
05Tissue protectionMuscle, lung, liver, endothelial and neuronal cells
06Neuronal and bone supportNeurite formation and osteoblast proliferation
07Cellular vitality and healthy ageingTelomerase, senescence and inflammaging markers

Abbreviations

PBMCs: Peripheral blood mononuclear cells
NK: Natural killer
TNF-α: Tumor necrosis factor alpha
IL-1β: Interleukin-1 beta
IL-6: Interleukin-6
IL-8: Interleukin-8
MIP-1α: Macrophage inflammatory protein-1 alpha
IgE: Immunoglobulin E
CXCR3: C-X-C motif chemokine receptor 3
ATP: Adenosine triphosphate

Quantitative findings from in-house in-vitro functional assays and preclinical models. Mechanistic evidence supporting potential functional benefits, not direct clinical outcomes. In vitro · preclinical.

Concluding Perspective

Concluding perspective

The scientific profiling of Dabur Chyawanprash represents a continuum from classical Ayurvedic knowledge to contemporary evidence-based investigation.

The traditional concept of Chyawanprash as a Rasayana provides the foundation for investigating multiple dimensions of health, vitality, resilience, immunity, and healthy ageing. Modern scientific investigations have enabled these broad concepts to be translated into measurable clinical, physiological, cellular, and molecular endpoints.

Clinical investigations have generated human evidence across areas including respiratory and allergy-associated health, seasonal illness, general wellbeing, and cytogenetic protection. Of particular interest, the clinical investigation in bidi smokers demonstrated significant reductions in cytogenetic abnormalities following Chyawanprash consumption, providing human evidence supporting a potential genoprotective effect in the context of tobacco-smoke-associated cellular damage.

The in-house biological programme further demonstrated activity across a broad range of functional domains. These included enhancement of cellular ATP production, antioxidant activity, NK-cell function, macrophage phagocytosis, dendritic-cell signaling, modulation of IgE and histamine responses, respiratory-cell protection, endothelial inflammatory signaling, liver and muscle-cell protection, osteoblast proliferation, neuronal protection, and modulation of cellular ageing-associated pathways.

Systems-level research framework

45 Ayurvedic ingredients
Phytochemical fingerprint
Molecular targets and biological pathways
Proteomics + Transcriptomics + Metabolomics + Lipidomics
Cellular and preclinical phenotypes
Human biomarkers and clinical outcomes
Integrated biological network model

Overall scientific evidence model

Importantly, these findings do not suggest that DCP operates through a single molecular target. Rather, the overall evidence is consistent with the scientific hypothesis that a complex polyherbal formulation may influence multiple interconnected biological pathways simultaneously.

The convergence of evidence across clinical, preclinical, cellular, and molecular investigations therefore provides a progressively deeper understanding of DCP.

Thus, the scientific evolution of DCP can be viewed not simply as the validation of individual traditional ingredients or isolated biological effects, but as the progressive development of an integrated evidence framework connecting:

Ayurvedic knowledge → Formulation science → Biological mechanisms → Clinical evidence → Systems biology → Measurable health outcomes

The current evidence supports DCP as a multi-component, multi-domain formulation with demonstrated biological activity spanning immune responsiveness, respiratory wellbeing, antioxidant defence, cellular protection, physiological resilience, and selected ageing-associated pathways.

At the same time, the evidence highlights important opportunities for future research. Integration of proteomics, transcriptomics, metabolomics, microbiome analysis, human biomarker studies, network pharmacology, and artificial intelligence can further define the molecular signature of DCP and establish relationships between formulation composition, biological pathways, cellular responses, and human health outcomes.

This provides the scientific foundation for the continued evolution of Dabur Chyawanprash from a traditionally recognized Rasayana formulation toward a scientifically characterized, multi-dimensional health and wellness formulation.